89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.
Hematological and biochemical parameters were evaluated in 31 patients receiving 150 MBq 89Strontium (89Sr) intravenously due to painful skeletal metastases from hormone resistant prostate cancer. Two and 3 months after the injection prostate specific antigen (PSA) had increased by a median of 36% and 100%, respectively, as compared to the pretreatment value whereas alkaline phosphatase (APHOS) had decreased by about 20% (median). The leucocyte and platelet counts were reduced by about 20-35%, without reaching grade greater than or equal to 2 toxicity. Pain relief was reported in 14 of 29 evaluable patients at 2 months and in 11 of 23 patients at 3 months. It is concluded that 89Sr represents a worthwhile therapeutic modality in the palliation treatment of patients with hormone resistant prostate cancer, though the biological significance of frequently increasing PSA and decreasing APHOS is not yet completely understood.
Fosså
S D
SD
Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
Paus
E
E
Lochoff
M
M
Backe
S M
SM
Aas
M
M
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000700:Analgesics / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000532:radiotherapy / Q000556:secondary*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D059408:Pain Management; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000532:radiotherapy*; D011877:Radionuclide Imaging; D013326:Strontium Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D013667:Technetium / Q000627:therapeutic use
D000700:Analgesics; D014408:Biomarkers, Tumor; D013326:Strontium Radioisotopes; D013667:Technetium; D000469:Alkaline Phosphatase